The Mectizan® Donation Program (MDP or the Program) is an international program working to eliminate two diseases: onchocerciasis (also known as river blindness) and lymphatic filariasis (LF or elephantiasis). MDP is primarily funded by Merck & Co., Inc., Kenilworth, N.J., U.S.A.,* with support from GlaxoSmithKline (GSK). Merck donates Mectizan for the elimination of river blindness and lymphatic filariasis. GSK donates albendazole, which is co-administered with Mectizan for LF elimination.
These two debilitating parasitic diseases cause pain, suffering, and stigmatization. With sustained, annual treatment over time, transmission of both diseases can be eliminated. In the Americas, four of the six endemic countries no longer suffer from river blindness. In Africa, Togo no longer suffers from LF. MDP is committed to ending the suffering by eliminating these diseases worldwide.
*Merck & Co., Inc., Kenilworth, N.J., U.S.A., is known as MSD outside of the United States and Canada.